Enveric Biosciences
ENVB
0 hedge funds and large institutions have $94K invested in Enveric Biosciences in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
95% less capital invested
Capital invested by funds: $1.76M → $94K (-$1.67M)
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.24M |
| 2 |
TA
Tiedemann Advisors
New York
|
-$245K |
| 3 |
Millennium Management
New York
|
-$155K |
| 4 |
Goldman Sachs
New York
|
-$46K |
| 5 |
FCH
Freestone Capital Holdings
Seattle,
Washington
|
-$17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Bank of New York Mellon
New York
| $42K | – | – | – |
|
2
Renaissance Technologies
New York
| $12K | – | – | – |
|
3
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $11K | – | – | – |
|
|
PAM
4
Panagora Asset Management
Boston,
Massachusetts
| $10K | – | – | – |
|
5
Acadian Asset Management
Boston,
Massachusetts
| $5K | – | – | – |
|
6
UBS Group
Zurich,
Switzerland
| $4K | – | – | – |
|
|
CS
7
Cannell & Spears
New York
| $3K | – | – | – |
|
|
SBH
8
Segall Bryant & Hamill
Chicago,
Illinois
| $3K | – | – | – |
|
|
BCM
9
Bayesian Capital Management
Brooklyn,
New York
| $2K | – | – | – |
|
10
Citadel Advisors
Miami,
Florida
| $2K | – | – | – |
|
|
11
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$1.24M | -1 | Closed |
|
12
Bank of America
Charlotte,
North Carolina
| – | -$4K | – | – |
|
|
FCH
13
Freestone Capital Holdings
Seattle,
Washington
| – | -$17K | – | – |
|
|
14
Goldman Sachs
New York
| – | -$46K | – | – |
|
|
15
Millennium Management
New York
| – | -$155K | – | – |
|
|
TA
16
Tiedemann Advisors
New York
| – | -$245K | – | – |
|
|
TSS
17
Two Sigma Securities
New York
| – | -$16K | – | – |
|
ENVB Hedge Fund Activity: Q4 2018 in Review
0 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q4 2018, worth a combined $94K — down 95% from $1.76M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ENVB and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $1.24M sold.
- 0 institutional investors held Enveric Biosciences (ENVB) as of Q4 2018, down from 1 in Q3 2018.
- Funds reported $94K of Enveric Biosciences stock for Q4 2018, down 95% quarter-over-quarter.
- 0 funds opened new Enveric Biosciences positions in Q4 2018 and 1 closed out, a net change of -1 holder.
- The largest Enveric Biosciences seller in Q4 2018 was Hudson Bay Capital Management, an estimated $1.24M sold.
Based on aggregated 13F filings for Q4 2018.